• Consensus Rating: Buy
  • Consensus Price Target: $27.70
  • Forecasted Upside: 67.68 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$16.52
▲ +0.17 (1.04%)

This chart shows the closing price for EXEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Exelixis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EXEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EXEL

Analyst Price Target is $27.70
▲ +67.68% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $27.70, with a high forecast of $42.00 and a low forecast of $21.00. The average price target represents a 67.68% upside from the last price of $16.52.

This chart shows the closing price for EXEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Exelixis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/16/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/14/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/13/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/13/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/9/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/8/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/2/2022CowenLower Target$26.00 ➝ $21.00Low
11/2/2022CowenLower Target$26.00 ➝ $21.00Low
11/2/2022Royal Bank of CanadaLower TargetOutperform$31.00 ➝ $29.00Low
11/2/2022Morgan StanleyLower TargetEqual Weight$23.00 ➝ $22.00Low
11/1/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$28.00Low
10/18/2022JMP SecuritiesInitiated CoverageOutperform$26.00N/A
8/15/2022CowenBoost Target$26.00N/A
7/26/2022Piper SandlerBoost TargetOverweight$30.00 ➝ $32.00Low
7/15/2022Morgan StanleyBoost TargetEqual Weight$22.00 ➝ $23.00Low
6/23/2022BMO Capital MarketsInitiated CoverageOutperform$28.00Low
5/12/2022Jefferies Financial GroupInitiated CoverageBuy$28.00Medium
3/14/2022Piper SandlerLower Target$34.00 ➝ $30.00High
2/18/2022HC WainwrightLower TargetBuy$52.00 ➝ $42.00High
11/19/2021Piper SandlerInitiated CoverageOverweight$34.00High
11/3/2021Royal Bank of CanadaLower TargetOutperform$32.00 ➝ $31.00High
11/3/2021HC WainwrightLower TargetBuy$65.00 ➝ $52.00High
11/2/2021OppenheimerLower TargetOutperform$30.00 ➝ $29.00Medium
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$28.00Medium
9/20/2021HC WainwrightReiterated RatingBuy$65.00Low
9/20/2021Truist FinancialLower TargetBuy$37.00 ➝ $36.00High
9/9/2021HC WainwrightReiterated RatingBuy$65.00Low
8/6/2021HC WainwrightBoost TargetBuy$35.00 ➝ $64.00High
6/29/2021HC WainwrightReiterated RatingBuy$47.00 ➝ $35.00Low
6/29/2021OppenheimerLower TargetOutperform$35.00 ➝ $27.00Medium
6/28/2021Needham & Company LLCLower TargetBuy$33.00 ➝ $30.00High
6/15/2021HC WainwrightInitiated CoverageBuy$47.00Medium
4/19/2021Morgan StanleyLower TargetEqual Weight$27.00 ➝ $26.00Low
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$30.00High
3/11/2021Wolfe ResearchInitiated CoverageOutperform$35.00Medium
2/16/2021Piper SandlerBoost TargetOverweight$33.00 ➝ $36.00Low
1/15/2021William BlairReiterated RatingBuyN/A
12/16/2020Morgan StanleyLower TargetEqual Weight$29.00 ➝ $27.00Low
10/26/2020Stifel NicolausBoost TargetHold$26.00 ➝ $27.00Low
9/22/2020Morgan StanleyBoost TargetEqual Weight$23.00 ➝ $29.00Low
9/21/2020OppenheimerBoost TargetOutperform$33.00 ➝ $37.00Low
9/21/2020Piper SandlerBoost TargetOverweight$30.00 ➝ $33.00High
8/14/2020William BlairReiterated RatingBuyHigh
8/7/2020Morgan StanleyBoost TargetEqual Weight$22.00 ➝ $23.00Medium
7/15/2020Morgan StanleyBoost TargetEqual Weight$21.00 ➝ $22.00Low
7/8/2020SunTrust BanksReiterated RatingBuy$40.00Low
6/2/2020William BlairReiterated RatingBuyMedium
6/1/2020OppenheimerInitiated CoverageBuy$28.00 ➝ $32.00Medium
5/14/2020SunTrust BanksBoost TargetPositive ➝ Buy$35.00 ➝ $40.00High
5/6/2020BMO Capital MarketsBoost TargetMarket Perform$20.00 ➝ $27.00Medium
5/6/2020Needham & Company LLCReiterated RatingBuy$33.00Medium
5/6/2020Piper SandlerBoost Target$23.00 ➝ $30.00Medium
5/6/2020Morgan StanleyBoost TargetEqual Weight$20.00 ➝ $21.00Low
4/21/2020GuggenheimBoost Target$27.00 ➝ $32.00High
4/21/2020BarclaysReiterated RatingBuy$30.00High
4/21/2020OppenheimerBoost TargetOutperform$25.00 ➝ $28.00High
4/20/2020Needham & Company LLCBoost TargetBuy$28.00 ➝ $33.00Medium
3/25/2020Piper SandlerReiterated RatingBuy$23.00High
3/13/2020William BlairReiterated RatingBuyLow
3/4/2020BarclaysInitiated CoverageOverweight$26.00Medium
2/27/2020Piper SandlerLower Target$35.00 ➝ $23.00Medium
2/26/2020BMO Capital MarketsBoost TargetMarket Perform$19.00 ➝ $20.00Medium
2/26/2020Stifel NicolausBoost TargetHold$21.00 ➝ $23.00Medium
2/26/2020CowenReiterated RatingBuyMedium
2/14/2020William BlairReiterated RatingBuyLow
2/11/2020Piper SandlerReiterated RatingBuy$35.00High
1/27/2020Needham & Company LLCReiterated RatingBuy$28.00Low
1/13/2020SunTrust BanksInitiated CoverageBuy$31.00High
1/13/2020Bank of AmericaReiterated RatingBuy$22.00 ➝ $21.00High
1/12/2020CowenReiterated RatingBuy$23.00Low
1/9/2020William BlairReiterated RatingBuyLow
12/13/2019Needham & Company LLCReiterated RatingBuy$30.00Low
12/13/2019CowenReiterated RatingBuy$23.00Low
11/13/2019Bank of AmericaInitiated CoverageBuy$22.00High
10/31/2019Piper Jaffray CompaniesLower Target$45.00 ➝ $35.00High
10/15/2019GuggenheimLower TargetBuy$33.00 ➝ $25.00High
10/8/2019BMO Capital MarketsLower TargetMarket Perform$23.00 ➝ $19.00Medium
8/1/2019Stifel NicolausBoost TargetHold$22.00 ➝ $23.00High
7/31/2019CowenSet TargetBuy$25.00N/A
7/15/2019CowenSet TargetBuy$25.00Medium
5/2/2019Morgan StanleySet TargetHold$27.00High
4/23/2019CowenReiterated RatingBuy$29.00High
3/19/2019OppenheimerReiterated RatingBuyLow
3/18/2019Morgan StanleyUpgradeUnderweight ➝ Equal Weight$24.80High
3/1/2019Piper Jaffray CompaniesReiterated RatingOverweight$48.00Low
2/26/2019CowenReiterated RatingBuy$29.00Low
2/22/2019BMO Capital MarketsInitiated CoverageMarket Perform$23.00Low
2/13/2019OppenheimerLower TargetOutperform$40.00 ➝ $31.00Low
11/15/2018OppenheimerSet TargetBuy$40.00Medium
11/5/2018Piper Jaffray CompaniesLower TargetOverweight$29.00 ➝ $26.00Low
11/1/2018OppenheimerSet TargetBuy$40.00High
9/17/2018GuggenheimInitiated CoverageBuyHigh
9/17/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$22.00High
9/10/2018Morgan StanleyInitiated CoverageUnderweight ➝ Underweight$19.00Medium
8/1/2018Stifel NicolausLower TargetHold ➝ Hold$29.00 ➝ $25.00Low
5/11/2018Needham & Company LLCLower TargetBuy ➝ Buy$33.00 ➝ $30.00High
5/10/2018Piper Jaffray CompaniesLower TargetOverweight$33.00 ➝ $29.00High
5/3/2018Stifel NicolausLower TargetHold ➝ Hold$30.00 ➝ $29.00High
4/11/2018William BlairReiterated RatingBuyLow
2/27/2018Stifel NicolausBoost TargetHold ➝ Hold$29.00 ➝ $30.00High
2/27/2018OppenheimerUpgradeMarket Perform ➝ Outperform$40.00High
2/27/2018UBS GroupUpgradeMarket Perform ➝ OutperformHigh
2/12/2018William BlairReiterated RatingOutperformMedium
1/17/2018OppenheimerReiterated RatingHoldHigh
1/4/2018OppenheimerReiterated RatingHoldMedium
12/21/2017SunTrust BanksReiterated RatingBuy$38.00High
12/19/2017OppenheimerReiterated RatingHoldLow
(Data available from 12/8/2017 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 23 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
5/12/2022
  • 7 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 5 very negative mentions
6/11/2022
  • 8 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 5 very negative mentions
7/11/2022
  • 4 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/10/2022
  • 6 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
9/9/2022
  • 11 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
10/9/2022
  • 13 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
11/8/2022
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2022

Current Sentiment

  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Exelixis logo
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $16.52
Low: $16.08
High: $16.61

50 Day Range

MA: $16.44
Low: $14.96
High: $17.39

52 Week Range

Now: $16.52
Low: $14.87
High: $23.40

Volume

1,272,028 shs

Average Volume

2,351,515 shs

Market Capitalization

$5.33 billion

P/E Ratio

17.39

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Exelixis?

The following Wall Street sell-side analysts have issued stock ratings on Exelixis in the last twelve months: BMO Capital Markets, Cowen Inc, Cowen Inc., EF Hutton Acquisition Co. I, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Morgan Stanley, Piper Sandler, Royal Bank of Canada, StockNews.com, and TheStreet.
View the latest analyst ratings for EXEL.

What is the current price target for Exelixis?

10 Wall Street analysts have set twelve-month price targets for Exelixis in the last year. Their average twelve-month price target is $27.70, suggesting a possible upside of 69.4%. HC Wainwright has the highest price target set, predicting EXEL will reach $42.00 in the next twelve months. Cowen Inc. has the lowest price target set, forecasting a price of $21.00 for Exelixis in the next year.
View the latest price targets for EXEL.

What is the current consensus analyst rating for Exelixis?

Exelixis currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EXEL will outperform the market and that investors should add to their positions of Exelixis.
View the latest ratings for EXEL.

What other companies compete with Exelixis?

How do I contact Exelixis' investor relations team?

Exelixis' physical mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company's listed phone number is (650) 837-7000 and its investor relations email address is [email protected] The official website for Exelixis is www.exelixis.com. Learn More about contacing Exelixis investor relations.